scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy

scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy

Although the hedgehog (HH) pathway is known to be deregulated in medulloblastoma, inhibitors of the pathway have shown disappointing clinical benefit. Using single-cell sequencing in a mouse model of the disease, the authors show that the response to the HH pathway inhibitor vismodegib is cell-type...

Full description

Bibliographic Details
Main Authors: Jennifer Ocasio, Benjamin Babcock, Daniel Malawsky, Seth J. Weir, Lipin Loo, Jeremy M. Simon, Mark J. Zylka, Duhyeong Hwang, Taylor Dismuke, Marina Sokolsky, Elias P. Rosen, Rajeev Vibhakar, Jiao Zhang, Olivier Saulnier, Maria Vladoiu, Ibrahim El-Hamamy, Lincoln D. Stein, Michael D. Taylor, Kyle S. Smith, Paul A. Northcott, Alejandro Colaneri, Kirk Wilhelmsen, Timothy R. Gershon
Format: Article
Language:English
Published: Nature Publishing Group 2019-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-13657-6
Description
Summary:Although the hedgehog (HH) pathway is known to be deregulated in medulloblastoma, inhibitors of the pathway have shown disappointing clinical benefit. Using single-cell sequencing in a mouse model of the disease, the authors show that the response to the HH pathway inhibitor vismodegib is cell-type specific.
ISSN:2041-1723

Similar Items